MAPT and Alzheimer disease: The overwhelming investment in AD drug discovery has been focused on two mechanisms: 1) Reducing amyloid plaque load in the brain (the hallmark of AD diagnosis; 70-80% of the effort) and 2) preventing tau phosphorylation.